Progress Report: Steven Frank, MD
Investigator: Steven Frank, MD– Assistant Professor, University of Texas, M.D. Anderson Cancer Center C4 and MRI-based Prostate Brachytherapy Brachytherapy is a form of radiotherapy where a radiation source, called “seeds”, is precisely implanted into the prostate such that emitted radiation will abolish the tumor. Recent technological advances have increased the. Read More
Progress Report: Adam S. Feldman, MD, MPH
Investigator: Adam S. Feldman, MD, MPH–Assistant Professor of Surgery, Massachusetts General Hospital, Harvard School of Medicine Active Surveillance: Identifying When to Treat and When Not to Treat In 2010 nearly 218,000 men will be diagnosed with prostate cancer in the United States. However, ~50% of those men will have low. Read More
Progress Report: Eleni Efstathiou, MD, Ph.D
Investigator: Eleni Efstathiou, MD, PhD – Assistant Professor, University of Texas, M.D. Anderson Cancer Center Biomarker Driven Application of Therapy Androgens (male hormones such as testosterone) fuel prostate cancer growth and survival. Androgens are synthesized in the testis and adrenal glands. Therapeutic agents that block the production of androgens (androgen. Read More
Progress Report: Scott Dehm, Ph.D
Investigator: Scott Dehm, PhD – Assistant Professor, University of Minnesota Mechanisms of Androgen Receptor (AR) Activation in Prostate Cancer The standard first line treatment strategy for metastatic prostate cancer is androgen (male hormones) deprivation therapy, such as Lupron, which reduces the level of circulating testosterone (type of androgen), or such. Read More
Progress Report: Atish Choudhury, MD, Ph.D
Investigator: Atish Choudhury, MD, PhD – Instructor in Medicine, Dana-Farber Cancer Institute Molecular Determinants of Hormone Refractory Prostate Cancer Metastatic prostate cancer initially responds to androgen deprivation therapy (ADT; blockade of male hormones such as testosterone) resulting in tumor regression and improved clinical performance. This is because prostate cancer cell. Read More
Progress Report: Steve Y. Cho, MD
Investigator: Steve Y. Cho, MD – Assistant Professor, Johns Hopkins University Translation of [18F]DCFBC PET:A Novel Prostate Imaging Biomarker Positron Emission Tomography (PET) is a molecular imaging technique that can produce a 3-D image of human cancers. This system works by injecting a patient with a radionuclide tracer (a compound. Read More
Progress Report: Gerhardt Attard, MD, Ph.D
Investigator: Gerhardt Attard, MD, PhD – Assistant Professor, Institute for Cancer Research, Royal Marsden Hospital, London Predicting Resistance to Abiraterone: Molecular Analysis of CTCs First-line treatment for recurrent prostate cancer involves blockade of male hormone (testosterone; androgen) production in a process known as androgen deprivation therapy (ADT). Androgens are synthesized. Read More
Progress Report: Mohamed Simon Arredouani, Ph.D
Investigator: Mohamed Simon Arredouani, PhD – Assistant Professor, Beth Israel Deaconess Medical Center Advances in Prostate Cancer Immunotherapy The immune system protects humans and other mammals from disease by recognizing foreign invaders such as bacteria and viruses. It is also thought that tumor cells express molecules foreign to the patient. Read More
Progress Report: Andrew Armstrong, MD, MSc
Investigator: Andrew Armstrong, MD, MSc – Associate Professor, Duke University Linking Epithelial and Stemness Plasticity with Prostate Cancer Metastasis and the Lethal Phenotype The mechanism by which cancer cells spread from the primary tumor to distant sites in the body (the process of metastasis) is not fully understood. Scientists hypothesize. Read More
Progress Report: John Ward, MD
Investigator: John Ward, MD– Assistant Professor, M.D. Anderson Cancer Center, University of Texas Noninvasive Radiofrequency Field for the Targeted Destruction of Prostate Cancer Using Directed Gold Nanoparticles—Activated Gold Particles Could Provide Novel Means of Destroying Tumors Dr. Ward is investigating a new way to kill prostate cancer cells by targeting. Read More